Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
Amanda Cashen, Mark Juckett, Alcee Jumonville, Mark Litzow, P. J. Flynn, John Eckardt, Betsy LaPlant, Kristina Laumann, Charles Erlichman, John DiPersioТом:
91
Мова:
english
Сторінки:
6
DOI:
10.1007/s00277-011-1240-1
Date:
January, 2012
Файл:
PDF, 131 KB
english, 2012